SEAAIS 2020 75th Annual Meeting

September 19, 2020 to September 20, 2020

The SEAAIS 2020 virtual meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology Society. The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 9.5 contact hours.

Commercial Support
This activity is supported by educational grants from CSL Behring and Astra Zeneca.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Examine biologics available for the treatment of asthma and discuss recommendations that can be made choosing a biologic for an asthma patient.
  2. Examine testing methods for metal allergy patients.
  3. Review common dermatologic conditions treated by allergists and identify improved treatment options.
  4. Review other uses for biologics such as treating hives and nasal polyps.
  5. Review USP guidelines and updates for compliance.
  6. Illustrate lean processes that providers can implement to increase efficiency and discuss major sources with literature where they can learn about lean healthcare.
  7. Review guidelines and principles to assist providers with the recognition, diagnosis and management of patients with occupational asthma.
  8. Illustrate the clinical manifestation of exercise-induced anaphylaxis and discuss the pathophysiologic events during exercise that precipitate symptoms.



Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

Course summary
Available credit: 
  • 9.50 AMA PRA Category 1 Credit™
  • 9.50 Attendance
  • 9.50 CBRN
Course opens: 
Course expires: 
Event starts: 
09/19/2020 - 9:00am CDT
Event ends: 
09/20/2020 - 3:30pm CDT

All identified conflicts of interest have been resolved.

Lee S. Clore, Jr., MD – CME Planner, Moderator
Speaker/honorarium – Boehringer Ingelheim, Genentech, GSK, Regeneron
Advisor Board Member/honorarium – GSK, Pfizer, Sanofi

Patricia Stewart, MD – CME Planner
Speaker/honorarium – Genentech

Thomas Casale, MD – Speaker
Speaker/honorarium – Genentech
Consultant/consulting fees – Genentech, Regeneron, Sanofi
Advisory Board/honorarium – AstraZeneca, GSK
Author/honorarium – Genentech
DSMB/honorarium -  Novartis

David Cohen, MD – Speaker
Consultant/consulting fees – Dermavant, Dermira, Evommune, Leo, Ferndale, Medimetriks, UCB
Advisory Board/honorarium – Asana, Leo, UCB

Mike Tankersley, MD – Speaker
Consultant/consulting fees – ALK

James Tracy, DO – Speaker
Consultant/consulting fees – Thermo Fisher
Advisory Board/honorarium - Pharming

The following have nothing to disclose:
Jean L. Owen, MBA – Meeting Planner
Anna Feldweg, MD – Speaker
Alexandra Freeman, MD – Speaker
Jerome Goddard, PhD – Speaker
Stephen LeBlanc, MD - Speaker
Karin Pacheco, MD – Speaker
Panida Sriaroon, MD – Speaker

Available Credit

  • 9.50 AMA PRA Category 1 Credit™
  • 9.50 Attendance
  • 9.50 CBRN
Please login or create an account to take this course.